Brenda Z (Fuzapladib Sodium) – Injectable for Acute Canine Pancreatitis Management

Targeted Relief for Acute Canine Pancreatitis

Acute pancreatitis in dogs can escalate rapidly — causing severe pain, vomiting, and life-threatening systemic inflammation. Brenda Z (Fuzapladib Sodium for Injection) is an innovative veterinary therapeutic that directly targets the neutrophilic inflammation driving the acute phase, helping dogs recover faster and more comfortably.

How Brenda Z Works

Brenda Z is a leukocyte function-associated antigen-1 (LFA-1) activation inhibitor. It works by blocking neutrophil migration into the inflamed pancreatic tissue — interrupting the hallmark neutrophilic inflammation that causes tissue damage during acute pancreatitis. By targeting this specific inflammatory pathway, Brenda Z helps manage clinical signs at the source rather than simply masking symptoms.

Why Choose Brenda Z?

• Mechanism-targeted therapy — specifically inhibits LFA-1 to block neutrophil-driven pancreatic inflammation
• Fast-acting injectable formulation — designed for use during the critical acute phase when rapid intervention matters most
• Clinically recognized — first introduced in Japan (as ブリンダZ) and recognized globally as equivalent to Panoquell-CA1
• Addresses the root inflammatory process — goes beyond supportive care to actively modulate the immune response in the pancreas

Product Details

• Active Ingredient: Fuzapladib Sodium
• Formulation: Injectable solution
• Pack Size: 4 ml bottle
• Indication: Acute canine pancreatitis management
• Also known as: Panoquell-CA1 (international markets), ブリンダZ (Japan)

Recommended Use

Brenda Z is a veterinary-prescribed injectable medication for use under professional supervision. It is indicated for the management of clinical signs during the acute phase of canine pancreatitis. Dosing and administration should be determined and performed by a qualified veterinarian.